SCHEMBL12675784

SCHEMBL12675784

COc1ncc(F)cc1CNc1ccc(C(=O)c2cn(S(=O)(=O)c3ccccc3)c3ncc(Br)cc23)c(F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.41
CYP2C9 P11712 4/20 0.40
KIT P10721 3/20 0.40
CYP2C19 P33261 2/20 0.40
KDR P35968 2/20 0.40
FLT3 P36888 2/20 0.40
AURKC Q9UQB9 2/20 0.40
CSF1R P07333 1/20 0.40
ATM Q13315 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MMP1 P03956 3/20 0.32
MMP9 P14780 3/20 0.32
MMP13 P45452 3/20 0.32
ADAM17 P78536 1/20 0.31
ENPP3 O14638 1/20 0.31
ENPP1 P22413 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12675786 0.86 HTR6 (0.40) MMP1MMP9MMP13DRD2HTR7
SCHEMBL1884462 0.86 CYP3A4 (0.50) CYP3A4CYP2C9KITCYP2C19KDR
SCHEMBL15474217 0.80 MET (0.40) CYP3A4KDRFLT3HTR6
SCHEMBL12675783 0.77 ENPP3 (0.38) CYP2C19MEN1KMT2AENPP3ENPP1
SCHEMBL1894844 0.72 MEN1 (0.59) MEN1KMT2AENPP3ENPP1SMN1; SMN2
SCHEMBL1884464 0.71 CYP3A4 (0.51) CYP3A4CYP2C9KITCYP2C19KDR
SCHEMBL1885535 0.70 CYP2C9 (0.47) CYP3A4CYP2C9DRD2HTR7HTR6
SCHEMBL1887574 0.70 CYP3A4 (0.40) CYP3A4CYP2C9KITCYP2C19KDR
SCHEMBL2237476 0.70 LMNA (0.56) CYP2C19MEN1KMT2AENPP3ENPP1
SCHEMBL2599952 0.69 CYP3A4 (0.58) CYP3A4CYP2C9KITCYP2C19KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP3A4 3717/4885CYP2C9 3884/4885KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.